In this approach, tissues that are growing abnormally are treated to keep them from turning cancerous and spreading. Interception is already being trialled for breast and skin cancers, among others. But now the success of a new drug that quashes pancreatic tumours is raising scientists' hopes that interception could succeed even for this recalcitrant cancer. Cancer interception was one of the main themes at last week's American Association for Cancer Research Conference (AACR) on Pancreatic Cancer in San Diego, California ' the first such meeting since the US Food and Drug Administration approved the landmark pancreatic-cancer drug daraxonrasib (Rasonque) in August. Its success has renewed optimism that researchers can combine it or other emerging therapies with early-detection methods to revolutionize how pancreatic tumours are treated. A combination of early-detection techniques and interception is 'going to be the breakthrough strategy that really changes survival', says Diane...
learn more
